Halozyme Therapeutics, Inc. (HALO) Stock Price & How to Invest

Halozyme Therapeutics licenses drug delivery technology instead of selling many drugs of its own. Its core asset is rHuPH20, a recombinant human hyaluronidase branded ENHANZE, which temporarily breaks down hyaluronan in the subcutaneous space so a large-volume biologic can be injected under the skin in minutes rather than infused for hours. Roche, Janssen, Takeda, argenx, Pfizer, AbbVie, Eli Lilly, Bristol-Myers Squibb, GSK and Incyte are among the licensees, and ENHANZE now sits inside ten commercialized products across more than 100 markets. Halozyme takes upfront and milestone payments plus royalties averaging a mid-single-digit percentage of partner sales, and it separately sells bulk rHuPH20 to those partners, plus two proprietary products (Hylenex and XYOSTED) and auto-injector devices inherited from the Antares Pharma acquisition.

The investment picture is a royalty stream growing quickly into a known patent date. In Q2 2026 revenue rose ~48% to ~$481.0 million, of which ~$307.7 million (~64%) was royalties, ~$129.6 million was product sales and ~$43.7 million was collaboration revenue; net income was ~$229.9 million on ~$287.7 million of operating income, margins only a licensing model produces. The counterweight is that the issued US patent covering rHuPH20 expires in 2027 (Europe 2029, with additional patents valid into 2029), and collaboration terms generally step the royalty rate down in a country once those patents lapse there and no other valid claim covers the product. Halozyme's answer is the MDASE patent estate (US patents expiring 2032 to 2034, Europe 2032), which it is asserting against Merck over subcutaneous Keytruda, plus the Hypercon and Surf Bio hyperconcentration platforms bought in late 2025 whose patents run into the mid-2040s.

The 2027 US rHuPH20 patent expiry is a dated, contractually specified step-down in royalty rates in countries where no other valid claim covers a partner product, and no amount of revenue growth removes that clock. Concentration remains high: DARZALEX alone was roughly half of Q2 royalties, and partners can generally terminate an ENHANZE agreement on 90 days notice. Competitive substitution is real, since Merck chose a rival hyaluronidase route for subcutaneous Keytruda and other developers are pursuing the same alternative, which is precisely what the MDASE litigation is about; an adverse PTAB or appellate outcome would weaken that estate. The balance sheet carries ~$2.18 billion of convertible principal against roughly ~$231.9 million of cash and investments at June 30, 2026, so the model depends on royalty cash flow continuing to convert cleanly. Finally, the Elektrofi and Surf Bio platforms are early: Hypercon has been demonstrated non-clinically and Surf Bio was preclinical at acquisition, so the mid-2040s patent life is only worth what partners eventually commercialize.

9 analysts publish price targets on HALO, averaging $88.22 against a $103.12 price as of August 2026, or -14.4%. The published targets run from $70.00 to $105.00, a moderate spread, and the ratings split 6 buy, 3 hold, 0 sell. Over the last six months there have been 6 raises and 1 cut among the published actions. A price target is what an analyst published on a date, not a prediction, and sell-side ratings skew positive across the whole market.

Read the full HALO forecast and price target for the target table, the recent rating actions by firm, and how the consensus has shifted.

We give no verdict on Halozyme Therapeutics, Inc.. Both cases are real, which is why the question is contested at all, so here is the strongest version of each.

The case for buying. Royalty compounding from products launched since 2020. Q2 2026 royalties of ~$307.7 million were up ~50% year over year, led by DARZALEX at ~$152.2 million (+27%) and VYVGART Hytrulo at ~$72.6 million (+143%), with Phesgo at ~$28.4 million and all other products at ~$54.4 million (+85%). The most optimistic published target, $105.00, assumes this works close to its best case.

The case against. The 2027 US rHuPH20 patent expiry is a dated, contractually specified step-down in royalty rates in countries where no other valid claim covers a partner product, and no amount of revenue growth removes that clock. The most pessimistic target, $70.00, is roughly what HALO is worth if this bites instead.

Read the full bull and bear case on HALO, including what would have to change to break either one. Walnut is not an investment adviser.

A simple financial snapshot. These are approximations and refresh quarterly; for current figures see Halozyme Therapeutics, Inc.'s investor relations page or your broker.

• Revenue (TTM): ~$1.66B
• Royalty share of revenue (Q2 2026): ~64% (~$307.7M of ~$481.0M)
• 2026 revenue guidance (raised Aug 6): ~$1.835B to ~$1.910B
• 2026 non-GAAP diluted EPS guidance: ~$8.65 to ~$9.00
• Market cap: ~$11.7B (~$103 per share)
• Convertible debt vs cash and investments: ~$2.18B principal vs ~$232M

The stock rose about 20% on August 7, 2026 after Q2 results beat and guidance was raised for total revenue, royalties, adjusted EBITDA (~$1.225B to ~$1.280B) and EPS. At roughly $103 that is about 30 times trailing GAAP earnings, which are depressed by the ~$284.9 million in-process R&D charge and ~$48.7 million intangible impairment taken in Q4 2025, and closer to 12 times the midpoint of 2026 non-GAAP EPS guidance. On an enterprise basis (~$13.6B including net debt) the shares trade near 7 times guided 2026 revenue and roughly 11 times guided adjusted EBITDA, a multiple that embeds some expectation that royalties survive the 2027 patent step-down.

If you want HALO exposure as part of a larger bundle rather than directly, these ETFs hold it meaningfully. Weights are approximate and refresh quarterly.

Other names that sit close to HALO: same theme, named as a direct competitor, or held beside it in the same funds. Each entry says which. Worth a look if you are thinking about diversification within a thesis rather than concentration on one ticker.

There are three common ways to get HALO exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it (FBT), which spreads the position across many companies. Or build it into a focused thematic portfolio, so HALO sits alongside other stocks that express the same thesis.

Walnut takes the portfolio route. Describe a thesis where HALO fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.

New to this? Start with how to invest in stocks, see how to analyze a stock with AI, or compare the best AI stock analyzers.

HALO is a high-margin royalty compounder whose valuation hinges on whether MDASE, Hypercon and contractual royalty terms carry the stream past the 2027 rHuPH20 patent expiry.

Whether HALO is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is HALO a buy or a sell?, and where the stock could go from here in the HALO stock forecast.

For income investors, whether HALO pays a dividend and how the payout looks is covered in does HALO pay a dividend? And to weigh HALO against a peer, read the full side-by-side comparisons: HALO vs ALT and HALO vs RPRX.